ClinicalTrials.gg
Enrolling by invitationNCT07301762Updated Sep 10, 2026

Automated Manual Lymphatic Drainage Therapy to Improve Glymphatic Function in OSA Patients

An interventional study of Automated manual lymphatic drainage therapy (AMLDT) device in Obstructive Sleep Apnea (OSA), OSA and Obstructive Sleep Apnea, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Sleep Apnea, Obstructive by Mayo Clinic — 6 open to participants now, 6 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Mayo Clinic.

Planned enrollment
10th of 11
15 · median 43
Started
2025
with 1 other
No phase
8 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Sleep Apnea, Obstructive by Mayo Clinic, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 with no phase, and was the 16th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 17 studies in Sleep Apnea, Obstructive by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sleep Apnea, Obstructive by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to investigate whether enhancing systemic lymphatic drainage improves glymphatic function in patients with obstructive sleep apnea (OSA).

Read the detailed description

This proof-of-concept, pre-post open-label clinical trial will enroll 12 adult patients aged 50 and older with previously treated OSA (≥6 months of CPAP adherence). Participants will undergo biomarker testing and sleep architecture analysis using ambulatory home sleep trackers (Somfit) before and after one month of nightly AMLDT intervention.

The significance of this study lies in its potential to uncover a novel, non-invasive therapeutic approach to enhance glymphatic clearance during sleep in OSA patients. The anticipated findings may inform future strategies for mitigating the risk of neurodegenerative diseases through targeted manipulation of the lymphatic system.

03

Conditions studied

  • Obstructive Sleep Apnea (OSA)
  • OSA
  • Obstructive Sleep Apnea

Keywords

  • obstructive sleep apnea
  • OSA
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 years and older
  • Diagnosed with obstructive sleep apnea
  • On stable, effective, and compliant CPAP therapy for a minimum of 6 months
  • Willing and able to provide
  • Willing and able to use automated manual lymphatic drainage device (Neuroglide) nightly for 1-month and participate in at-home sleep monitoring
  • Stable on a medication regimen for comorbid medical or mental health disorders for at least 3 months and not planning to undergo therapy adjustment during trial

Exclusion criteria

Exclusion Criteria:

  • Chronic kidney disease ( (GFR) \< 60 mL/min/1.73 m² for 3 months or more), due to its potential impact on serum biomarker clearance
  • Other primary sleep disorders aside from OSA (i.e., narcolepsy, REM Sleep behavior disorder, chronic insomnia, restless legs syndrome), circadian rhythm disorder or shift work
  • Chronic neurological disorders (e.g. Multiple sclerosis, epilepsy, neurodegenerative disorders, ALS), due to their impact on biomarkers. History of headache (\<15 days a month) and stroke (over 6 months prior to enrollment) are allowed
  • Physical limitations preventing the use of Neuroglide device (e.g. inability to lay on the back due to pain, inability to setup the device due to limb dysfunction/weakness)
  • Physical limitations preventing the use or function of Somfit, including forehead skin lesions, history of adhesive allergies, implanted electronic devices (e.g. pacemakers) or the use of CPAP masks with forehead support/bar/pad (Fisher \& Paykel Vitera, Fisher \& Paykel Eson, ResMed Mirage Quattro, ResMed Ultra Mirage Full Face Mask, Philips Respironics ComfortGel Blue), because the forehead piece of the mask would prevent the appropriate application of Somfit for at-home sleep monitoring. Because Somfit algorithms are based on physiological signals that include heart rate and it has not been validated in patients with persistent arrhythmia, we will exclude patients with history of atrial fibrillation and high PVC burden to avoid inaccurate estimates.
  • Acute cardiopulmonary disorders, infections, injury at/near the application site, abnormal lymphatic system due to previous surgery involving lymphatics or chronic lymphedema, acute inflammatory process (e.g. recent knee/hip surgery, upper respiratory tract infection, cancer not in remission)
  • Kokmen short test of mental status \< 34 (concern for mild cognitive impairment)
  • Inability to comply with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Other
    Intervention

    Open-Label intervention

    Device: Automated manual lymphatic drainage therapy (AMLDT) device

Interventions

  • DeviceAutomated manual lymphatic drainage therapy (AMLDT) device

    The AMLDT device (Neuroglide) is an FDA-cleared Class II medical device (K202693) for over-the-counter use for pain. It mimics manual lymphatic drainage through a pneumatic mat that performs rhythmic inflation and deflation in ascending fashion.

06

What researchers measure

Primary outcomes

  1. Difference in serum biomarkers

    Samples will be processed and tested for: * Aβ42 * Aβ40 * Aβ42/Aβ40 ratio * Phospho-tau 217 (p-tau-217) * Neurofilament light chain (NfL) * Glial fibrillary acidic protein (GFAP)

    Time frame: Baseline and Day 31

Secondary outcomes

  1. Differences in Pittsburgh Sleep Quality Index (PSQI)

    Differences in Pittsburgh Sleep Quality Index (PSQI) scores. Scoring ranges from 0-21 with higher scores indicating poorer sleep quality.

    Time frame: Baseline and Day 31

Other outcomes

  1. Differences in sleep macro-structure and microstructure

    Assessment of correlation between changes in sleep macrostructure (Nonrapid eye movement sleep stages 1-3 \[%\], sleep duration \[minutes\], sleep efficiency \[%\]) and microstructure (power spectral density of slow wave activity \[µV²/Hz\]) and changes in serum biomarkers (1-42/1-40 \[ratio\], pTau181 \[pg/mL\], neurofilament light chain \[pg/mL\], and GFAP \[pg/mL\] ).

    Time frame: Baseline and Day 31

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 508 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 13 months is below that.

Counting every sponsor, half of 624 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2025
First posted
Dec 24, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07301762
Lead sponsor
Mayo Clinic
Responsible party
Diego Zaquera Carvalho (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Dec 24, 2025
Start date
Nov 24, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 10, 2026

Study contacts

Diego Zaquera Carvalho, M.D., M.S.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion